Kyverna Therapeutics, Inc. (KYTX) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Kyverna Therapeutics, Inc. (KYTX:NASDAQ), powered by AI.

Current Price
$7.92
P/E Ratio
-2.2
Market Cap
351M
Sector
Healthcare
What is the Kyverna Therapeutics, Inc. stock price forecast?

Kyverna Therapeutics, Inc. is currently trading at $7.92. View real-time AI analysis on Alpha Lenz.

What is Kyverna Therapeutics, Inc. insider trading activity?

View the latest insider trading data for Kyverna Therapeutics, Inc. on Alpha Lenz.

What is Kyverna Therapeutics, Inc.'s P/E ratio?

Kyverna Therapeutics, Inc.'s P/E ratio is -2.2.

Kyverna Therapeutics, Inc.

NASDAQ · KYTX
$7.92-0.23(-2.82%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Kyverna Therapeutics, Inc.'s future dividend policy...
Alpha Chat Insight

Kyverna Therapeutics, Inc. trades at a P/E of -2.2 (undervalued) with modest ROE of -64.7%.

Ask for details

Company Overview

Kyverna Therapeutics Inc. is a biotechnology company pioneering innovative therapeutics focusing on autoimmune diseases. Kyverna's primary goal is to harness cell therapies to target and suppress the immune system's harmful autoimmune responses. The company's unique approach lies in its development of engineered T cell therapies designed to reset the immune system's balance, potentially providing long-lasting relief from debilitating conditions. With operations driven by cutting-edge research and development, Kyverna Therapeutics is at the forefront of a transformative field impacting the healthcare sector. In the broader market, this biotech firm represents a significant advance in the ongoing search for effective, less invasive therapies for chronic autoimmune disorders, tapping into a growing demand for solutions that can improve quality of life for millions globally. Headquartered in the United States, Kyverna Therapeutics continues to leverage innovative science to revolutionize treatment paradigms for autoimmune conditions.

CEOMr. Warner Biddle
SectorHealthcare
IndustryBiotechnology
Employees129

Company Statistics

FY 2025

Profile

$350.54MMarket Cap
$0.00Revenue
0.00Shares Out
129Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

-2.17P/E
1.51P/B
N/AEV/Sales
-1.61EV/EBITDA
-2.26P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-53.91%ROA
-64.67%ROE
-53.74%ROIC

Financial Health

$124.09MCash & Cash Equivalents
$-62.54MNet Debt
26.50%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Kyverna Therapeutics, Inc. (ticker: KYTX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 129 employees. Market cap is $351M.

The current price is $7.92 with a P/E ratio of -2.17x and P/B of 1.51x.

ROE is -64.67%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Kyverna Therapeutics, Inc. (KYTX) Stock Forecast 2026 $7.92 — Price, Financials & Analyst Targets | Alpha Lenz